Clinical Trial

A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.
Protocol Amendment History 2 changes
notable Enrollment reduced: 3000 -> 2150 participants 2026-07-08
notable Trial sites expanded: 40 -> 71 locations 2026-07-08
Trial Details
NCT Number NCT07606066
Lead Sponsor AstraZeneca
Conditions Type 2 Diabetes
Enrollment 2,150 participants
Start Date 2026-05-06
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-07